risk-stratification
(7)
DexaFit
DexaFit is a health-testing company that turns a quick, low-radiation full-body DXA scan into a broad picture of a person's health - body composition, bone density, visceral fat and metabolic markers. Its AI arm, DexaFit Dx, layers machine learning on top of those same scans to screen for major chronic diseases such as coronary artery disease and type 2 diabetes, aiming to catch them early and non-invasively. Founded in Chicago in 2011 and now operating dozens of centers, DexaFit pairs in-person testing with an app that translates results into longevity scores, disease-risk estimates and trackable goals.
Delfina
Delfina is a San Francisco-based maternal health company that pairs an AI-powered clinical platform with a consumer pregnancy app to make prenatal care proactive rather than reactive. Its predictive models flag rising risk - preterm birth, hypertensive disorders, gestational diabetes - while patients track vitals from home and connect around the clock with bilingual virtual doulas, dietitians, and mental health support. Founded in 2021 by physician-scientist Dr. Senan Ebrahim and his co-founders, Delfina sells to health plans, providers, and employers, and has raised roughly $22M to date, including a $17M Series A in January 2025.
Radial
Radial (Radial Analytics, Inc.) is a Concord, Massachusetts healthcare technology company that builds AI-driven decision support software for value-based care. Its flagship platform, Smart Placement, uses machine learning and natural language processing to help hospitals, health plans, and accountable care organizations decide - in real time - which patients can safely recover at home instead of in a skilled nursing facility after a hospital stay. Founded in 2014 by former Locately co-founders Thaddeus Fulford-Jones and Eric Weiss alongside physician Anant Vasudevan, Radial applies 'nudge theory' at clinical crossroads moments to lower costs and improve outcomes without overriding clinician judgment.
Valar Labs
Valar Labs is a Palo Alto precision-oncology company building AI tests that read the pathology slides already made during routine cancer care. Its Vesta platform applies proprietary foundation models to standard H&E-stained tissue images to predict how individual patients will respond to therapy - starting with bladder cancer, where it forecasts whether a patient is likely to benefit from BCG treatment and stratifies the risk of recurrence and progression. Founded in 2021 by Stanford AI researchers, the company has raised $26M total and earned the FDA's first Breakthrough Device Designation for an AI digital-pathology prognostic test in bladder cancer.
DeLorean Artificial Intelligence
DeLorean Artificial Intelligence is a Palm Beach, Florida-based healthcare AI company that builds predictive and interventive intelligence to forecast chronic disease and recommend next-best clinical actions before a patient gets sicker. Its flagship Medical AI platform, MARTI, analyzes structured and unstructured health records to predict events like hospitalizations and disease progression - and is described as the first medical AI to be biologically validated by independent third parties. Founded in 2019 by Dr. Severence MacLaughlin, the company also applies its predictive engine to sales/CRM, life sciences, financial services and other industries.
Diagnostic Robotics
Diagnostic Robotics is an AI healthcare company building medical-grade triage and clinical-prediction software for health plans and providers. Its models, trained on tens of billions of claims data points and nearly 100 million patient visits, forecast avoidable ER visits, congestive heart failure deterioration and serious mental illness, then steer patients into the right care pathway. Founded in 2017 by Kira Radinsky, Jonathan (Yonatan) Amir and Moshe Shoham, the company is a Mayo Clinic Platform portfolio company and closed a $45M Series B in 2022.
Clairity, Inc.
Clairity is a Boston-based healthtech company that built Clairity Breast, the first FDA-authorized AI platform that predicts a woman's five-year risk of breast cancer directly from a routine screening mammogram. Founded by Harvard radiologist Dr. Connie Lehman, the company turns images already sitting in the medical record into a forward-looking risk score, aiming to move breast care from late-stage detection toward early, equitable prevention.